These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33044315)

  • 1. The effects of adding long-acting injectable antipsychotic drugs to clozapine on relapse and hospitalization in patients with treatment-resistant schizophrenia: a mirror-image retrospective study.
    Caliskan AM; Karaaslan M; Inanli I; Caliskan S; Arslan M; Esra Cicek I; Eren I
    Int Clin Psychopharmacol; 2021 Jan; 36(1):30-33. PubMed ID: 33044315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study.
    Nielsen J; Jensen SO; Friis RB; Valentin JB; Correll CU
    Schizophr Bull; 2015 May; 41(3):627-36. PubMed ID: 25180312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial Effects of Concomitant Long-Acting Injectable Antipsychotics on Time to Rehospitalization in Patients With Treatment-Resistant Schizophrenia Receiving Clozapine: A Retrospective Cohort Study.
    Tien Y; Wang XY; Huang SC; Huang HP
    J Clin Psychiatry; 2024 May; 85(2):. PubMed ID: 38696112
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study.
    Bioque M; Parellada E; García-Rizo C; Amoretti S; Fortea A; Oriolo G; Palau P; Boix-Quintana E; Safont G; Bernardo M
    Eur Psychiatry; 2020 Jul; 63(1):e71. PubMed ID: 32669145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
    Kishimoto T; Nitta M; Borenstein M; Kane JM; Correll CU
    J Clin Psychiatry; 2013 Oct; 74(10):957-65. PubMed ID: 24229745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study.
    Mahlich J; Olbrich K; Wilk A; Wimmer A; Wolff-Menzler C
    Clin Drug Investig; 2020 Apr; 40(4):355-375. PubMed ID: 32152867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clozapine augmentation with long-acting antipsychotic injections: A case series and systematic review.
    Oloyede E; Dima A; Taylor D; Cheung H; Dzahini O; Shergill S; Whiskey E
    Acta Psychiatr Scand; 2023 Dec; 148(6):538-552. PubMed ID: 37899506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics on Time to Rehospitalization Within 1 Year of Discharge in Elderly Patients With Schizophrenia.
    Lin CH; Chen FC; Chan HY; Hsu CC
    Am J Geriatr Psychiatry; 2020 Jan; 28(1):23-30. PubMed ID: 31481273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal.
    Suzuki T
    Expert Opin Drug Deliv; 2016; 13(2):253-64. PubMed ID: 26636244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Impact of drug-reimbursement policies on prescribing: A case-study of a newly marketed long-acting injectable antipsychotic among relapsed schizophrenia patients".
    Jackson JW; Fulchino L; Rogers J; Mogun H; Polinski J; Henderson DC; Schneeweiss S; Fischer MA
    Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):95-104. PubMed ID: 29168261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies.
    Haddad PM; Taylor M; Niaz OS
    Br J Psychiatry Suppl; 2009 Nov; 52():S20-8. PubMed ID: 19880913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Clozapine With Long-Acting Injectable Antipsychotics in Treatment-Resistant Schizophrenia: Preliminary Evidence From Health Care Utilization Indices.
    Grimminck R; Oluboka O; Sihota M; Rutherford DL; Yeung H
    Prim Care Companion CNS Disord; 2020 Jul; 22(4):. PubMed ID: 32678523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics.
    Lin CH; Chen FC; Chan HY; Hsu CC
    Int J Neuropsychopharmacol; 2019 Sep; 22(9):541-547. PubMed ID: 31260538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the impact of COVID-19 on medication adherence and health care utilization among individuals with psychotic disorders who are prescribed long-acting injectables (LAIs) or clozapine: A population-based study in Manitoba, Canada.
    MacMillan-Wang YW; Hensel JM; Leong C; Jayas R; Valencia E; Yorski A; Liu K
    Schizophr Res; 2024 Sep; 271():345-352. PubMed ID: 39089102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study.
    Montemagni C; Del Favero E; Cocuzza E; Vischia F; Rocca P
    Ther Adv Psychopharmacol; 2022; 12():20451253221122526. PubMed ID: 36226272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of antipsychotic monotherapy and polypharmacy in schizophrenia patients with clozapine treatment: A nationwide, health insurance data-based study.
    Joo SW; Kim H; Jo YT; Ahn S; Choi YJ; Choi W; Park S; Lee J
    Eur Neuropsychopharmacol; 2022 Jun; 59():36-44. PubMed ID: 35550204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies.
    Kishimoto T; Hagi K; Nitta M; Leucht S; Olfson M; Kane JM; Correll CU
    Schizophr Bull; 2018 Apr; 44(3):603-619. PubMed ID: 29868849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Subjective Experiences and Effectiveness of First-Generation Long-Acting Injectable Antipsychotics and Risperidone Long-Acting Injectables in Patients With Schizophrenia.
    Chen WY; Lin SK
    J Clin Psychopharmacol; 2016 Oct; 36(5):492-5. PubMed ID: 27580495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Acting Injectables Versus Oral Antipsychotics: A Retrospective Bidirectional Mirror-Image Study.
    Miura G; Misawa F; Kawade Y; Fujii Y; Mimura M; Kishimoto T
    J Clin Psychopharmacol; 2019; 39(5):441-445. PubMed ID: 31415288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.